Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Incretin

Base Information
  • Chemical Name:Incretin
  • CAS No.:100040-31-1
  • Molecular Formula:C226H338N60O66S
  • Molecular Weight:4983.53
  • Hs Code.:
  • Mol file:100040-31-1.mol
Incretin

Synonyms:Incretin;54241-84-8;Incretins;UNII-DG3AZ5DMT2;DG3AZ5DMT2;UNII-1O4H75S7H2;1O4H75S7H2;PD078139

Suppliers and Price of Incretin
Supply Marketing:
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • Tocris
  • GIP(human)
  • 1
  • $ 458.00
  • Sigma-Aldrich
  • Gastric Inhibitory Polypeptide human ≥95% (HPLC)
  • 0.1 mg
  • $ 325.00
  • Sigma-Aldrich
  • Gastric Inhibitory Polypeptide human ≥95% (HPLC)
  • .1mg
  • $ 314.00
  • Sigma-Aldrich
  • Gastric Inhibitory Polypeptide human ≥95% (HPLC)
  • 0.5 mg
  • $ 1310.00
  • Sigma-Aldrich
  • Gastric Inhibitory Polypeptide human ≥95% (HPLC)
  • .5mg
  • $ 1270.00
  • ApexBio Technology
  • GIP(human)
  • 1mg
  • $ 520.00
  • Alfa Aesar
  • Gastric Inhibitory Peptide, human
  • 1mg
  • $ 286.00
  • Alfa Aesar
  • Gastric Inhibitory Peptide, human
  • 0.5mg
  • $ 135.00
Total 33 raw suppliers
Chemical Property of Incretin
Chemical Property:
  • Appearance/Colour:White Powder 
  • PSA:0.00000 
  • LogP:0.00000 
  • Storage Temp.:−20°C 
  • XLogP3:-25.2
  • Hydrogen Bond Donor Count:70
  • Hydrogen Bond Acceptor Count:75
  • Rotatable Bond Count:168
  • Exact Mass:4982.4724468
  • Heavy Atom Count:353
  • Complexity:12400
Purity/Quality:

99%, *data from raw suppliers

GIP(human) *data from reagent suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:

Total 1 MSDS from other Authors

Useful:
  • Canonical SMILES:CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CCCCN)C(=O)NC(CC7=CN=CN7)C(=O)NC(CC(=O)N)C(=O)NC(C(C)CC)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC1=CC=C(C=C1)O)N
  • Isomeric SMILES:CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
  • Recent ClinicalTrials:Epicardial Fat and Clinical Outcomes After Coronary Artery Bypass Grafting in Diabetics vs. Non Diabetics
  • Description GIP was originally isolated as a gastric inhibitory polypeptide. After the discovery of its glucose-dependent insulinotropic activity, known as the incretin effect, GIP was renamed glucose-dependent insulinotropic peptide. Gastric inhibitory peptideAbbreviation: GIPAdditional names: gastric inhibitory polypeptide,gastrointestinal inhibitory peptide, glucose-dependent, insulinotropic peptide
  • Uses GIP possessing incretin activity enhances glucosestimulated insulin release. GIP agonists are potentially useful for the treatment of diabetes. Moreover, DPP-4 inhibitors are approved for use in diabetes patients because GIP is rapidly deactivated by DPP-4.
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 100040-31-1